Ajanta Pharma Limited (AJANTPHARM:NSE) Annual Income Statement ()
AJANTPHARM:NSE Quarterly Financials ()
Frequently Asked Questions About Ajanta Pharma Limited (AJANTPHARM:NSE) Stock
Ajanta Pharma Limited's (AJANTPHARM:NSE) last reported annual revenue was INR 37.43 Billion.
Ajanta Pharma Limited's (AJANTPHARM:NSE) annual revenue growth rate based on the revenue reported in the past 5 years is : 12.69%
Ajanta Pharma Limited's(AJANTPHARM:NSE) is profitable as of its last reported annual financials.
The net profit margin for Ajanta Pharma Limited's(AJANTPHARM:NSE) from its laster reported year is 15.71%
The return on equity (ROE) for Ajanta Pharma Limited's(AJANTPHARM:NSE) from its last reported annual financials is : 18.64%
The return on assets (ROA) for Ajanta Pharma Limited's(AJANTPHARM:NSE) from its last reported annual financials is : 11.38%
The return on invested capital (ROIC) for Ajanta Pharma Limited's(AJANTPHARM:NSE) from its last reported annual financials is : 15.16%
The Debt to Equity ratio for Ajanta Pharma Limited's(AJANTPHARM:NSE) from its last reported annual financials is : 0.04%
The dividend yield for Ajanta Pharma Limited's(AJANTPHARM:NSE) from its laster reported year is 1.73%
Ajanta Pharma Limited's(AJANTPHARM:NSE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AJANTPHARM:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
